Clinical Edge Journal Scan

Advanced HCC: Lenvatinib plus nivolumab yields promising results in real-world


 

Key clinical point: Lenvatinib plus nivolumab shows a promising efficacy and safety profile against advanced hepatocellular carcinoma (HCC) in the real-world setting.

Major finding: The lenvatinib plus nivolumab vs lenvatinib group showed a higher objective response rate (45.0% vs 23.4%; P = .03) and longer progression-free survival (7.5 vs 4.8 months; P = .05) and overall survival (22.9 vs 10.3 months; P = .01). Only a few patients developed grade 3/4 toxicities, such as dermatitis (15.0%), gastrointestinal bleeding (7.5%), and hypertension (5.0%).

Study details: This was a retrospective study including 87 patients aged ≥20 years with advanced HCC who received lenvatinib plus nivolumab (n = 40) or lenvatinib alone (n = 47).

Disclosures: The study was funded by the Ministry of Health and Welfare and the Center of Excellence for Cancer Research and Taipei Veterans General Hospital. The authors declared no conflicts if interest.

Source: Wu W-C et al. Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience. Invest New Drugs. 2022 (Apr 28). Doi: 10.1007/s10637-022-01248-0

Recommended Reading

TACE vs. LR: Better prognosis in HCC with bile duct tumor thrombus?
Federal Practitioner
Post-LT HCC recurrence unaffected by donor sex
Federal Practitioner
Clinical Edge Journal Scan Commentary: HCC May 2022
Federal Practitioner
Psychosocial Barriers and Their Impact on Hepatocellular Carcinoma Care in US Veterans: Tumor Board Model of Care
Federal Practitioner
Early-stage HCC: OLT offers better survival outcomes than ablative therapies in the elderly
Federal Practitioner
Pembrolizumab monotherapy shows promise for untreated advanced HCC in phase 2
Federal Practitioner
Subsequent anticancer therapy after ICI treatment prolongs survival in HCC
Federal Practitioner
Does imaging surveillance intensity govern clinical outcomes in HCC?
Federal Practitioner
Laparoscopic anatomic hepatectomy achieves better follow-up outcomes than non-anatomical hepatectomy in HCC
Federal Practitioner
Advanced HCC: Immunotherapy vs chemotherapy improves survival
Federal Practitioner